anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Surgical excision is the treatment of choice for feline intracranial meningioma.
OBJECTIVES: To report clinical findings, complications, and outcomes following surgery for feline intracranial meningioma.
METHODS: Medical records (01/2000-01/2017) of cats that underwent surgical excision of an intracranial meningioma at our institution were reviewed. Patient data included signalment, clinical signs, surgical technique, complications, histopathologic diagnosis, survival time, and owners' answers to a satisfaction questionnaire. Survival was assessed using the Kaplan-Meier method and log-rank test.
RESULTS: Twenty-six cats were included in this study. The exact cause of death was known in 17 cases and was not related to meningioma in 9/17 cases. Overall median survival time was 881 days (95% confidence interval 518; 1248). The age of the cat did not influence survival (p = 0.94) or the occurrence of complications (p = 0.051). Complications occurred in 13/24 cats, including dramatic complications in 4/24 cats. Most complications appeared in the first 24 hours post-surgery (12/13). Males had more postoperative complications (p = 0.042), including more seizures (p = 0.016). Cats with cranioplasty had fewer complications (p = 0.021). Clinical recurrence was confirmed in 3 out of 17 cats. Recurrence-free survival time was 826 days. Most owners (12/14) were satisfied with the outcome.
CONCLUSIONS: Surgical treatment of intracranial meningioma in cats was associated with a long median survival time but also with a high rate of minor and major postoperative complications, including early postoperative seizures. Cranioplasty may reduce complications. Age at the time of surgery had no effect on outcomes.
In the short arm, bitemporal ECT is administered twice a week during the first 6 weeks. Afterwards, it is administered once a week during 4 weeks. After that, the patients will have one ECT every 3 weeks during 6 weeks. Lastly, patients will receive one ECT each month during 2 months.
The extracts have antiangiogenetic properties. They reduce a sector of the blood vessels which is observed in vivo on experimentaly induced tumours and show tumour-regrssive activity in vivo, as well as direct inhibition effect on tumour cellular lines. The method does not include the use of methylated solvent or product and enzymes. By it, a mixture of full cartilage in aqueous solution with neutral pH is produced, preferably pure water, which mixture is centrifuged and the sediment and the supernatant layer are preserved for further usage. The sediment is freeze-dried and is tested for antitumour and antiangiogenetic activity in vivo and in vitro, with and without supernatant layer. The supernatant layer has antiangiogenetic and tumour regressive activity in vivo. The composition of the supernatant layer is tested  in different ways and some of the active components are characterized by fractioning. The fractions are tested for their direct in vivo activity on cellular lines. It is assumed that the non-fractioned supernatant has in vitro activity. Freeze-drying essentially destroys the activity of these liquid fractions whilst in the solid extract such annihilation of activity is not observed.
A sleep monitoring application is installed on a mobile device. The mobile device is placed in a location when a user sleeps and records environmental sound. The sleep monitoring application determines indicators of sleep activity such as breathing sounds made by the user, and determines a sleep state of the user based on the indicators of sleep activity. Sleep disorders can be detected from the indicators of sleep activity. The sleep monitoring application may generate a report that summarizes the user's sleep states and alerts the user to any sleep disorders. The sleep monitoring application can use the environmental sound and the determined sleep states to determine ambient sound that is associated with good sleep. Later, if the sleep application determines the user is having problems sleeping, the sleep monitoring application can play the determined ambient sound to help the user sleep.
Group 2(n=50) FiO2%100, PaO2≥180mmHg MMSE will be applied to patients before surgery. At the determined measurement times body and blood temperature, SpO2, HR, MAP, PH, blood gas lactate, blood gas base deficit, urine output, PaO2, PaCO2, Htc, FiO2, right and left rSO2 values were monitored..In the postoperative period, at the 24th hour, when routine cardiological controls were performed 1., 3., 6. Simultaneous MMSE will be repeated in months.
Baseline assessments will include child and parent demographic data, medical history, and cognitive functioning, along with anthropometric measures such as height, weight, and body composition. Those who complete baseline assessments will be enrolled in one of two groups of family-based treatment on after-school evenings (8 pairs in each group; total of 16 child-caregiver pairs). A total of 24 weekly treatment sessions lasting up to 90 minutes each will be held over 6 months. Family-based behavioral treatment is a manualized, group intervention for children with obesity and their caregivers that incorporate participant-driven goal-based changes in diet and physical activity, and a variety of interactive educational session topics and behavioral support for reaching goals. A private weigh-in for children and caregivers will be conducted at each session. Sessions will begin with check-in with each family about weekly goal progress, after which the caregivers and children will split into separate groups for session-specific content including educational material tailored to nutrition, eating, and activity. The final portion of group session will involve children and caregivers merging in one group to share learning experiences and engage in collaborative goal-setting for the upcoming week(s). After the six month family-based behavioral intervention, baseline measures will be reassessed as well as overall program adherence. Program adherence will be evaluated using weekly program attendance and the number of days dietary/physical activity self-monitoring logs were completed.
FIELD: veterinary science, medicine, pharmacology. SUBSTANCE: invention relates to agent used for treatment of animals and humans with parasitic diseases caused by mites, insects, nematodes and complicated or noncomplicated with microflora. Ointment has avermectin complex consisting of avertin N, or aversectin C, or abamectin, or ivermectin and others as an antiparasitic agent and sulfur and dimethylsulf-oxide as an antibacterial and an anti-inflammatory agent and one of cellulose derivative (acetylcellulose, or methyl-cellulose, or cellulose acetophthalate, or microcrystalline cellulose, or hydroxypropylmethyl cellulose and others) as prolongator and dimethylsulfoxide, castor oil, lanolin as penetrating agent and softening skin. Methyluracil and ascorbic acid are used for recovery processes, acceleration of cellular regeneration and enhancement of resistance in host-organism. Polyethylene glycol-400 is used as a solvent. Vaseline is used as ointment base and all components are taken at the definite ratios. After once-twice applying ointment the proposed composition provides 100% curative, antiparasitic and anti-inflammatory efficiency being even in cases complicated with secondary infection as compared with treatment using the known analog. EFFECT: enhanced effectiveness of ointment. 3 cl, 7 ex
FIELD: agriculture.SUBSTANCE: invention relates to the field of agriculture, in particular, to equipment for processing, preservation of raw material of animal and vegetable origin. Plant for preservation of raw material of animal and plant origin includes mounted on skids a mobile module. Module consists of sealed thermo-housing with heat-insulated framework located on both sides of the module, dryers, heat carrier source, blower for forced air blowing, cassettes and device for catching biologically active volatile compounds. Plant is equipped with a wall installed in the thermo-housing with the formation of the operator's room for placement of a control controller, an automation cabinet and a weight meter of the product. Room is arranged with the possibility of the preservation mode installation by the operator depending on the type of raw material. Heat source used is a hot-water boiler with a heat exchanger installed in the operator's room. Latter is arranged in drying chamber. In wall of dryer housing there installed is for removal of moisture from drying chamber ventilation branch pipe with automatic gate and arranged before it rounded slope to improve directed movement of air flow. Each cassette for unfolding biological raw material is made with movable grate trays and has their inclination regulators. Device for trapping biologically active volatile compounds is detachable and can be installed on vent branch pipe. Plant is also equipped with a control cassette placed in the drier casing to control the moisture reducer connected to the product weight meter located in the operator's room.EFFECT: invention ensures achievement of technical result consisting in improvement of quality of products with high content of biologically active substances with simultaneous reduction of energy consumption, duration and labour intensity of preserving process.1 cl, 3 dwg
Muscular atrophy, which results in loss of muscle mass and strength, is a significant concern for patients with various diseases. It is crucial to comprehend the molecular mechanisms underlying this condition to devise targeted treatments. MicroRNAs (miRNAs) have emerged as key regulators of gene expression, serving vital roles in numerous cellular processes, including the maintenance of muscle stability. An intricate network of miRNAs finely regulates gene expression, influencing pathways related to muscle protein production, and muscle breakdown and regeneration. Dysregulation of specific miRNAs has been linked to the development of muscular atrophy, affecting important signaling pathways including the protein kinase B/mTOR and ubiquitin‑proteasome systems. The present review summarizes recent work on miRNA patterns associated with muscular atrophy under various physiological and pathological conditions, elucidating its intricate regulatory networks. In conclusion, the present review lays a foundation for the development of novel treatment options for individuals affected by muscular atrophy, and explores other regulatory pathways, such as autophagy and inflammatory signaling, to ensure a comprehensive overview of the multifarious nature of muscular atrophy. The objective of the present review was to elucidate the complex molecular pathways involved in muscular atrophy, and to facilitate the development of innovative and specific therapeutic strategies for the prevention or reversal of muscular atrophy in diverse clinical scenarios.
Risk Summary

Limited published studies report that metformin is present in human milk [see Error! Hyperlink reference not valid.]. However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metformin hydrochloride extended-release tablets and any potential adverse effects on the breastfed child from metformin hydrochloride extended-release tablets or from the underlying maternal condition.

Data

Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.
###  Adults

The initial dose for adults with seizure disorders should not exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of 0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects preclude any further increase. Maintenance dosage must be individualized for each patient depending upon response. Maximum recommended daily dose is 20 mg.

The use of multiple anticonvulsants may result in an increase of depressant adverse effects. This should be considered before adding clonazepam to an existing anticonvulsant regimen.

###  Pediatric Patients

Clonazepam is administered orally. In order to minimize drowsiness, the initial dose for infants and children (up to 10 years of age or 30 kg of body weight) should be between 0.01 and 0.03 mg/kg/day but not to exceed 0.05 mg/kg/day given in two or three divided doses. Dosage should be increased by no more than 0.25 to 0.5 mg every third day until a daily maintenance dose of 0.1 to 0.2 mg/kg of body weight has been reached, unless seizures are controlled or side effects preclude further increase. Whenever possible, the daily dose should be divided into three equal doses. If doses are not equally divided, the largest dose should be given before retiring.

###  Geriatric Patients

There is no clinical trial experience with clonazepam in seizure disorder patients 65 years of age and older. In general, elderly patients should be started on low doses of clonazepam and observed closely (see PRECAUTIONS, Geriatric Use).
Chemoradiotherapy: Patients undergo radiotherapy 5 days a week for 5.5 weeks. Beginning on day 1 and continuing concurrently with radiotherapy, patients receive gemcitabine IV over 30 minutes twice weekly and oral erlotinib once daily. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients with stable or responsive disease proceed to maintenance therapy. Maintenance therapy: Beginning 4-7 weeks after the completion of chemoradiotherapy, patients receive maintenance chemotherapy comprising gemcitabine IV over 30 minutes on days 1 and 8 and oral erlotinib once daily. Treatment repeats every 21 days for a total of 4 courses in the absence of disease progression or unacceptable toxicity.
Participants in the rTMS plus Text4Support group of the study would be assisted by a study team member assigned that purpose to register onto the Text4Support program. The process would require all participants to input their phone numbers into the Text4Support platform that will be used to deliver the daily messages. Starting a day after enrollment, participants will receive daily supportive text messages designed by mental health therapists, clinical psychologists, psychiatrists, and mental health service users. These messages are based on cognitive behavior therapy principles crafted to enhance positively the mood of its users with depressive symptoms and other related mental health problems of concern. The messages will be pre-programmed into a software program that will deliver the messages to participants automatically to the participants' mobile phones at 10 AM (Mountain Time) and 12 PM (Atlantic Time), and each participant will receive these messages continuously for 6 weeks.
HHHFNC has been proposed as an alternative to nasal continuous positive airway pressure (nCPAP) in neonatal intensive care units (NICUs) for preventing extubation failure. In a recent international survey on periextubation practices in extremely preterm infants, nCPAP was the most common type of respiratory support used (84%) followed by nasal intermittent positive pressure ventilation (55%) and HHHFNC (33%). Moreover, HHHFNC appears to have efficacy and safety similar to those of nCPAP when applied immediately post-extubation to prevent extubation failure in preterm infants. and resulted in significantly less nasal trauma in the first 7 days post-extubation than nCPAP. However, the best flow rates of HHHFNC to prevent extubation failure remains to be known.

This RCT aims to compare the efficacy and safety of postextubation respiratory support via HHHFNC at two different flow rates (6 L/min. versus 3 L/min) regarding successful extubation after a period of endotracheal positive pressure ventilation. We hypothesized that postextubation respiratory support via HHHFNC at a flow rate of 6 L/min. will result in a greater proportion of preterm infants being successfully extubated after a period of endotracheal positive pressure ventilation compared with HHHFNC at a flow rate of 3 L/min.
PURPOSE:To provide the titled colored liquid storable even at a high temperature without forming bubles, and resistant to the leak of the liquid, by compounding water, a water-miscible organic solvent, a water-soluble dye, etc. with a polyethylene glycol having a specific molecular weight, etc. CONSTITUTION:The objective colored liquid is produced by mixing (A) water, (B) a water-miscible organic solvent (e.g. ethylene glycol), (C) a water-soluble dye (e.g. an acidic dye such as Eosine C, a direct dye such as Water Black #100, or a basic dye such as Rhodamine B) and/or a water-dispersible pigment, (D) a polyethylene glycol of formula HOCH2(CH2OCH2)nCH2OH (n is molar number of ethylene oxide group) having an average molecular weight of 150-6,000, and if necessary, (E) a preservative, a dispersant, a rustproofing agent, a lubricant, and a water-soluble or water-dispersible resin. The liquid is used as a coloring ink of an applicator by filling in a cylindrical container furnished with the felt of marking pen, the tip of ball point pen, or a rigid or soft porous core at its top, and sealed at the rear end with a sealant such as high- viscosity grease.
Parotidectomy is the standard procedure for treatment of many parotid lesions, however it carries a lot of drawbacks. Facial asymmetry and Frey's syndrome are the most annoying complications to the patients. Insertion of inter-positioning grafts at parotidectomy bed can decrease these complications significantly. Free dermal fat graft (FDFG) and the superficial musculoaponeurotic system (SMAS) flap, have very promising results. In this study the investigators have compared the functional and esthetic outcome from their usage.

Seventy-eight patient underwent parotidectomy for various causes. The patients were divided randomly in 2 groups each group 39 patients. In one group FDFG was inserted at the parotidectomy bed, while in the other group SMAS flap was performed. Preoperative, operative, and postoperative data were recorded and analyzed.

The normality of distribution of variables was verified by Wilks -Shapiro test. The data were expressed as Number (No), percentage (%) mean (x̅) and standard deviation (SD). Chi-square test (χ2) was used to study association between qualitative variables. Whenever any of the expected cells were less than five, Fischer's Exact test was used. Student's t-test is a test of significance used for comparison of quantitative variables between two groups of normally distributed data, while Mann Whitney's test was used for comparison of quantitative variables between two groups of not normally distributed data. Two-sided P value was set to be significant if \< 0.05.
Obese insulin resistant individuals (n=70) as defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex and will be recruited. Participants will be asked to complete a total of 2 study visits. The second study visit will occur at 12 months (± 2 weeks) after the initial study visit.
Amiodarone hydrochloride, USP is a member of a class of antiarrhythmic drugs with predominantly Class III (Vaughan Williams' classification) effects. Amiodarone is a benzofuran derivative: 2-butyl-3-benzofuranyl 4-[2-(diethylamino)-ethoxy]-3,5-diiodophenyl ketone hydrochloride. 

The structural formula is as follows:

Amiodarone hydrochloride is a white to cream-colored crystalline powder. It is slightly soluble in water, soluble in alcohol and freely soluble in chloroform. It contains 37.3% iodine by weight.

Each amiodarone hydrochloride tablet intended for oral administration contains 200 mg of amiodarone hydrochloride. In addition each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, lactose monohydrate, magnesium stearate, povidone and sodium starch glycolate.
Spray solution to treat Athlete's foot:   An anti-fungal spray solution that can be used to treat and prevent athlete's foot. It contains an anti-fungal component and tea tree oil both dissolved in isopropyl alcohol.   The anti-fungal component is clotrimazol 1%. Tea tree oil in different strengths at least 5% used as a natural anti-fungal and antiseptic and also to overcome symptoms of athlete's foot. The solvent is isopropyl alcohol that will provide an antiseptic and dehydrating action.   The spray is used directly on the foot and between toes and also inside the shoes and socks.
Acute myeloid leukemia (AML) with t(7;12)(q36;p13) is a recurrent translocation in AML in infants or very young children and was recently included in the World Health Organization (WHO) Classification of Hematolymphoid Tumors. AML with t(7;12) is reported to involve MNX1 and ETV6 signaling; however, the mechanism of leukemogenesis is not well understood, and the presence of MNX1::ETV6 fusion transcripts has only been confirmed in approximately 50% of cases. In contrast, high expression of MNX1 has been seen in all investigated cases. In this study, we investigated the clinical as well as biological characteristics of 12 pediatric AML with t(7;12) and performed whole transcriptome (WTS) and whole genome sequencing (WGS) on six of these. There was no significant difference in event-free survival or overall survival of these t(7;12) AML patients compared with other AML in the same age group. Interestingly, WTS identified several fusion transcripts involving ETV6 but not together with MNX1. WGS identified the genomic breakpoints and revealed that a common fusion partner on chromosome 7 was NOM1. Principal component analysis (PCA) of the WTS data showed that all t(7;12) AML cases cluster together, separate from all other pediatric AML subtypes; all cases had high expression of MNX1, MNX1-AS1, and MNX1-AS2. Hence, t(7;12) AML, despite expressing different fusion transcripts and with varying translocation breakpoints, constitutes a phenotypically homogenous subgroup. This underlines that the leukemia-driving event most likely is ectopic expression of MNX1 and that this therefore should be the defining Classifying criteria of this type of AML.
In the placebo group, the 10 cm I-shaped tape was placed 5 cm inferior to the lateral epicondyle using the same Kinesio tape in the study group. It was applied transversely, starting from the painless side of the midline on the forearm extensor face directing towards the lateral side of the forearm without a tension.
This study is a phase Ib open label, single arm, adaptive multi-centre trial. Patients with unresectable locally advanced or metastatic HER2-positive breast cancer who previously received trastuzumab and a taxane, separately or in combination, will be treated with copanlisib (as assigned at registration according to the dose escalation scheme) plus trastuzumab emtansine 3.6mg/kg IV on day 1 of a 21-day cycle.